A bioinformatics screen identifies TCF19 as an aggressiveness‐sustaining gene in prostate cancer
Molecular Oncology · 2025
DOI: 10.1002/1878-0261.70118 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Amaia Ercilla und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Computational Biology. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Prostate cancer is a prevalent tumor type that, despite being highly curable, progresses to metastatic disease in a fraction of patients, thus accounting for more than 350 000 annual deaths worldwide. In turn, uncovering the molecular insights of metastatic disease is instrumental in improving the survival rate of prostate cancer patients. By means of gene expression meta‐analysis in multiple prostate cancer patient cohorts, we identified a set of genes that are differentially expressed in aggressive prostate cancer. Transcription factor 19 (TCF19) stood out as an unprecedented epithelial gene upregulated in metastatic disease, with prognostic potential and negatively associated with the activity of the androgen receptor. By combining computational and empirical approaches, our data revealed that TCF19 is required for full metastatic capacity, and its depletion influences core cancer‐related processes, such as tumor growth and vascular permeability, supporting the role of this gene in the dissemination of prostate tumor cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.
- Centro de Investigación Biomédica En Red de Cáncer (CIBERONC), Madrid, Spain.
- IKERBASQUE, Basque Foundation for Science, Barcelona, Spain.
- Endothelial Pathobiology and Microenvironment Group, Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.
- Cancer Science Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Spain.
- Translational Prostate Cancer Research Lab, CIC bioGUNE-Basurto, Biobizkaia Health Research Institute, Spain.
ORCID-Profile: Amaia Ercilla, Sara Del Palacio, Ianire Astobiza, Isabel Mendizabal, Mariona Graupera, Arkaitz Carracedo
Zitieren
APA
Ercilla, A., Crespo, J. R., Garcia-Longarte, S., Fidalgo, M., Del Palacio, S., Martin-Martin, N., Carlevaris, O., Astobiza, I., Fernández-Ruiz, S., Guiu, M., Bárcena, L., Mendizabal, I., Aransay, A. M., Graupera, M., Gomis, R. R., & Carracedo, A. (2025). A bioinformatics screen identifies TCF19 as an aggressiveness‐sustaining gene in prostate cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.70118
Vancouver
Ercilla A, Crespo JR, Garcia-Longarte S, Fidalgo M, Del Palacio S, Martin-Martin N, et al. A bioinformatics screen identifies TCF19 as an aggressiveness‐sustaining gene in prostate cancer. Molecular Oncology. 2025. doi:10.1002/1878-0261.70118
BibTeX
@article{Ercilla2025,
author = {Ercilla, Amaia and Crespo, Jana R and Garcia-Longarte, Saioa and Fidalgo, Marta and Del Palacio, Sara and Martin-Martin, Natalia and Carlevaris, Onintza and Astobiza, Ianire and Fernández-Ruiz, Sonia and Guiu, Marc and Bárcena, Laura and Mendizabal, Isabel and Aransay, Ana M and Graupera, Mariona and Gomis, Roger R and Carracedo, Arkaitz},
title = {A bioinformatics screen identifies TCF19 as an aggressiveness‐sustaining gene in prostate cancer},
journal = {Molecular Oncology},
year = {2025},
doi = {10.1002/1878-0261.70118}
}
EUVIMED